Silence of lncRNA CHRF protects H9c2 cells against lipopolysaccharide-induced injury via up-regulating microRNA-221.
Cardiac hypertrophy related factor (CHRF), a newly recognized long non-coding RNA (lncRNA), is a central regulator in cardiac hypertrophy responses. This study attempted to show the potential role of lncRNA CHRF in bacterial infection caused myocarditis. H9c2 cells were transfected with small interfering RNAs (siRNAs) specific for lncRNA CHRF alone or in combination with miR-221 inhibitor, and then subjected to lipopolysaccharide (LPS). The following parameters were measured: cell viability, apoptosis, reactive oxygen species (ROS) generation, pro-inflammatory cytokines release, microRNA (miR)-221 expression and the activation of nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) pathways. Silence of lncRNA CHRF impeded the LPS injury to H9c2 cells, as cell viability was increased (p < .05), apoptosis was inhibited (p < .05), ROS generation was decreased (p < .01), and the expression of interleukin (IL)-6 and tumor necrosis factor (TNF)-α was suppressed (p < .05). However, silence of lncRNA CHRF had no impacts on normal H9c2 cells growth (p > .05). miR-221 was negatively regulated by lncRNA CHRF (p < .01). LncRNA CHRF silence did not protect H9c2 cells against LPS when miR-221 was suppressed (p < .05 or p < .01). Also, the inhibitory effects of lncRNA CHRF silence on the activation of NF-κB and JNK pathways were flattened by miR-221 suppression (p < .05 or p < .01). These in vitro data collectively demonstrated that lncRNA CHRF silence protected H9c2 cells against LPS-induced injury via up-regulating miR-221 and modulating NF-κB and JNK pathways.